Author: GMP Insiders Expert Team

The GMP Insiders Expert Team is a group of seasoned professionals specializing in quality assurance, regulatory compliance, and operational innovation in pharmaceutical and biotech manufacturing. United by a passion for advancing Good Manufacturing Practices, they transform complex compliance challenges into clear, actionable strategies that drive operational excellence.

If you don’t find what you are looking for, try using a different term or contact us.

Method validation vs method verification: Key Differences

Difference Between Validation and Verification of Analytical Methods

Learn the key differences between method validation and verification in pharma labs, with clear guidance on when each applies and...
ich q1 stability testing draft released

ICH Q1 Draft Guideline Released for Comment: Consolidated Stability Framework Moves Forward

ICH Q1 draft released: a unified guideline for stability testing with new content on lifecycle, in-use studies, modelling, and advanced...
Melt granulation process (Principles, Mechanisms, and practical applications)

Melt Granulation: Principles, Mechanism, and Applications

Solvent-free melt granulation improves flowability, compressibility, and drug release. Learn its process, advantages, equipment, and pharma applications....
Ph.Eur. Proposes rFC Endotoxin Test Integration and Pyrogen Testing Updates

Ph. Eur. Proposes rFC Endotoxin Test Integration and Pyrogen Testing Updates

Ph. Eur. adds rFC to BET (2.6.14) and updates pyrogen testing (5.1.13) to support sustainable, animal-free methods in line with...
fda-warning-letter-analysis

FDA Issues Warning Letter to Yangzhou Sion Commodity Co., Ltd.

FDA warns Yangzhou Sion for CGMP violations, citing failures in component testing, QC oversight, and data integrity. CAPA plan and...
fda-warning-letter-analysis

FDA Warns Aspen SA Sterile Operations for CGMP Violations in Lab Controls, Aseptic Practices, Data Integrity, and Environmental Monitoring

The FDA has issued a warning letter to Aspen SA Sterile Operations for serious CGMP violations, including failures in lab...
fda-warning-letter-analysis

FDA Warns Linghai ZhanWang for Unsafe Materials, Stability Failures, and Poor Oversight

FDA issues a warning letter to Linghai ZhanWang for failing raw material testing, stability studies, and quality oversight, placing its...
Difference between reference and retention samples

Reference vs Retention Samples: What is the Difference?

Look into the key differences between reference and retention samples in pharma, their roles in GMP, storage rules, and regulatory...
fda-warning-letter-analysis

FDA Warning Letter Analysis: Chem-Tech, Ltd. – Deficiencies in OOS Investigation, Cleaning Validation and More

FDA issues a warning letter to Chem-Tech, Ltd. for improper OOS investigations, unvalidated cleaning procedures, and poor quality oversight. Key...
USP-NF Pharmacopeial Forum 51 - Draft proposals

USP–NF Proposed Drafts in PF 51(2): Key Highlights and Industry Impact

Discover the key updates in USP–NF PF 51(2), including revisions to chromatography, analytical instrument qualification, microbial contamination control, solubility measurements,...

BECOME A GMP INSIDER

Stay in touch and be the first to get the latest GMP News!